(Q45204128)

English

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

scientific article published in December 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

author name string

Rudolf Weide

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Annette Pandorf

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Jochen Heymanns

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Hubert Köppler

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

2445-2449

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190400004521

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1080%2F10428190400004521

21 January 2018

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

https://api.crossref.org/works/10.1080%2F10428190400004521

21 January 2018

Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190400004521

21 January 2018

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190400004521

21 January 2018

Identifiers

10.1080/10428190400004521

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45204128&oldid=2069807884"